Press Releases

Press Releases

Date Title
February 26, 2020
CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the Cowen
February 20, 2020
CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the SVB
February 13, 2020
ATLAS TM identifies Inhibigens tm that can undermine immunotherapy Dosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trial Progressed GEN-011 neoantigen cell therapy - IND filing expected in Q2 2020 Appointed Dr. Gisela Schwab to Genocea’s Board of Directors Conference call
February 6, 2020
CAMBRIDGE, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019 financial results and corporate update conference call and live audio webcast
Displaying 26 - 29 of 29